A Study of MHB036C for Advanced Solid Tumor

NCT06373406 | Active Not Recruiting Phase 1

• 1 other identifier: MHB036C-CP001CN
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors.

Conditions

Advanced Solid Tumor

Outcome Measures

Primary Outcomes (2)

• Incidence of participants with adverse events (AE)

  An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

  Until 30 days after last dose of MHB036C

• Number of participants with dose-limiting toxicity (DLT)

  DLTs will be assessed during the dose-escalation phase and are defined as toxicities related to MHB036C which meet pre-defined severity criteria and occurs within the first cycle of treatment

  At the end of Cycle 1 (each cycle is 21 days)

Secondary Outcomes (4)

• Maximum Plasma Concentration (Cmax)

  Until 30 days after last dose of MHB036C

• The area under the plasma concentration-time curve (AUC)

  Until 30 days after last dose of MHB036C

• To detectable anti-drug antibodies with treated subjects

  Until 30 days after last dose of MHB036C

• Objective response rate (ORR)

  Until 30 days after last dose of MHB036C

Study Arms (1)

MHB036C

EXPERIMENTAL

MHB036C IV every 3 weeks

Drug: MHB036C

Interventions

MHB036C DRUG

An antibody-drug conjugate therapy

MHB036C

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants voluntarily agree to participate in the study and sign the Informed Consent Form (ICF).
• Participants aged 18 years or older (inclusive), without gender limitation.
• Participants with Eastern Cooperative Oncology Group performance score of 0-1.
• Participants with expected survival time of more than 3 months.
• Eligible participants of childbearing potential (males and females) must agree to take reliable contraceptive measures (hormone or barrier method, or absolute abstinence, etc.) with their partners during the study and within at least 90 days after the last dose; female participants of childbearing potential must have a negative results of blood pregnancy test within 7 days before the first dose of the investigational product, and must be non-lactating.
• Participants who are able to understand study requirements, and willing and able to comply with arrangements of study and follow-up procedures.
• Participants to be enrolled in part one must have histologically or cytologically confirmed advanced or metastatic solid tumors, which have failed or are intolerant to standard of care (SOC), or for which no SOC is available;

You may not qualify if:

• Participants with 2 or more malignancies (except effectively treated non-melanoma skin cancer, cervical carcinoma in situ or other tumors, or malignancies considered cured) within 5 years prior to sign the Informed Consent Form.
• Participants who have received chemotherapy within 3 weeks prior to the first dose of investigational product, or have received anti-tumor therapy including radiation therapy, biologic therapy, endocrine therapy, immunotherapy, etc. within 4 weeks prior to the first dose; or participants with the following conditions:
• Medication of nitrosourea or mitomycin C within 6 weeks prior to the first dose of MHB036C;
• Medication of oral fluoropyrimidines or small molecule targeted agents within 5 half-lives of such drug before first dose of investigational product.
• Medication of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose of investigational product.
• Medication of other disapproved investigational products or therapies within 4 weeks prior to the first dose of investigational product.
• Presence of brain metastases and/or carcinomatous meningitis. Participants previously treated for brain metastases may be considered to be enrolled in this study, provided they have been in stable condition for at least 4 weeks, no evidence of new or enlarging brain metastases, or without steroid therapy within 14 days prior to the first dose of investigational product. This exception does not include carcinomatous meningitis, which should be excluded regardless of clinical stability.
• Participants previously received same targeted therapy will be excluded.
• Participants with adverse reactions from previous anti-tumor therapy that have not recovered to ≤Grade 1 as per CTCAE 5.0 (except for toxicities without safety risks as determined by the investigator, such as alopecia, hypothyroidism stably managed by hormone replacement therapy, etc.).

Sponsors & Collaborators

• Minghui Pharmaceutical (Hangzhou) Ltd: lead

Study Sites (1)

Shanghai Chest Hospital

Shanghai, 200030, China

Location

Study Officials

• Shun Lu

  Shanghai Chest Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2024
• First Posted: April 18, 2024
• Study Start: May 26, 2023
• Primary Completion: December 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: November 19, 2025

Record last verified: 2025-11

Locations

CN (1)